NasdaqGM - Delayed Quote USD

Trevi Therapeutics, Inc. (TRVI)

Compare
3.1200 0.0000 (0.00%)
At close: October 18 at 4:00 PM EDT
3.0700 -0.05 (-1.60%)
After hours: October 18 at 5:35 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Jennifer L. Good Co-Founder, CEO, President & Director 835.9k -- 1965
Dr. Thomas R. Sciascia M.D. Co-Founder & Chief Scientific Officer 551.43k -- 1953
Dr. James V. Cassella Ph.D. Chief Development Officer 50k -- 1955
Ms. Lisa Delfini Chief Financial Officer -- -- 1970
Mr. Christopher Galletta Controller & Chief Accounting Officer -- -- 1978
Katie McManus Communications Manager -- -- --
Mr. Farrell Simon Pharm.D. Chief Commercial Officer -- -- --
Ms. Danine Summers Vice President of Medical Affairs -- -- 1958

Trevi Therapeutics, Inc.

195 Church Street
16th Floor
New Haven, CT 06510
United States
203 304 2499 https://www.trevitherapeutics.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
26

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Corporate Governance

Trevi Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 10:59 AM UTC - November 11, 2024 at 12:00 PM UTC

Trevi Therapeutics, Inc. Earnings Date

Recent Events

October 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 19, 2024 at 1:35 PM UTC

at Cantor Global Healthcare Conference

August 8, 2024 at 8:30 PM UTC

Q2 2024 Earnings Call

August 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 29, 2024 at 12:00 AM UTC

ARS: Annual Report to Shareholders

April 26, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 20, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

Related Tickers